Skip to main content
Fig. 3 | Journal of Neuroinflammation

Fig. 3

From: Downregulation of metallothionein-2 contributes to oxaliplatin-induced neuropathic pain

Fig. 3

Impact of genetic modification of MT2 on Oxal-induced neuropathic pain in female rats. a MT2 protein expression in the spinal dorsal horn 10 days after the treatments. Representative western blots (top panels) and a summary of densitometric analysis (bottom graphs). *p < 0.05; n = 4. Female rats were treated with vehicle or Oxal (0.4 mg/100 g/day for five consecutive days) 21 days after intraspinal injection of AAV-MT2A-EGFP or AAV-EGFP. b Hind paw withdrawal threshold in the female rats treated in a. **p < 0.01 versus vehicle; #p < 0.05, ##p < 0.01 versus Oxal + AAV-EGFP; n = 6 in Oxal + AAV-EGFP, n = 9 in Oxal + AAV-MT2A-EGFP. c MT2 protein expression after intrathecal injection of MT2A or control siRNA in female rats. Representative western blots (top panels) and a summary of densitometric analysis (bottom graphs). **p < 0.01; n = 4. d Hind paw withdrawal threshold in female rats treated with intrathecal injection of MT2A or control siRNA. **p < 0.01 versus control siRNA; n = 7. Oxal, oxaliplatin

Back to article page